Literature DB >> 12531349

Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain.

L Salleras1, A Domínguez, N Cardeñosa.   

Abstract

During the fourth quarter of 1997, a vaccination campaign using the meningococcal C polysaccharide vaccine was carried out in 14 autonomous regions of Spain. The remaining three regions did not participate. In the last quarter of the year 2000, a mass vaccination campaign using the meningococcal C conjugated vaccine was carried out in all regions. In the year 2001 the incidence decreased in all regions, although the decrease was greater in regions that did not vaccinate in 1997. In contrast, case fatality rates did not decrease. During 2001, the incidence rate of meningococcal C disease was still lower (0.32 per 100000 persons-year) in the regions that vaccinated in 1997 with the polysaccharide vaccine than in those that did not (0.64 per 100000 persons-year).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531349     DOI: 10.1016/s0264-410x(02)00589-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.

Authors:  Robert Welte; Caroline L Trotter; W John Edmunds; Maarten J Postma; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway.

Authors:  Siamak P Yazdankhah; Paula Kriz; Georgina Tzanakaki; Jenny Kremastinou; Jitka Kalmusova; Martin Musilek; Torill Alvestad; Keith A Jolley; Daniel J Wilson; Noel D McCarthy; Dominique A Caugant; Martin C J Maiden
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

3.  Surveillance of adverse effects during a vaccination campaign against meningitis C.

Authors:  Anne Laribière; Ghada Miremont-Salamé; Hadrien Reyre; Abdelilah Abouelfath; Ludovic Liège; Nicholas Moore; Françoise Haramburu
Journal:  Eur J Clin Pharmacol       Date:  2005-11-18       Impact factor: 2.953

4.  Epidemiology of meningococcal disease in Switzerland, 1999-2002.

Authors:  H Jaccard Ruedin; B Ninet; E Pagano; P Rohner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-22       Impact factor: 3.267

5.  Meningococcal conjugate vaccines: optimizing global impact.

Authors:  Andrew Terranella; Amanda Cohn; Thomas Clark
Journal:  Infect Drug Resist       Date:  2011-09-21       Impact factor: 4.003

6.  Impact and effectiveness of meningococcal vaccines: a review.

Authors:  Lucia Helena De Oliveira; Barbara Jauregui; Ana Flavia Carvalho; Norberto Giglio
Journal:  Rev Panam Salud Publica       Date:  2017-12-20

7.  Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.

Authors:  Myint Tin Tin Htar; Sally Jackson; Paul Balmer; Lidia Cristina Serra; Andrew Vyse; Mary Slack; Margarita Riera-Montes; David L Swerdlow; Jamie Findlow
Journal:  BMC Public Health       Date:  2020-12-09       Impact factor: 3.295

8.  The spectrum of acute bacterial meningitis in elderly patients.

Authors:  Pere Domingo; Virginia Pomar; Natividad de Benito; Pere Coll
Journal:  BMC Infect Dis       Date:  2013-02-27       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.